Skip to content

Evaluation of the Effects of Diacylglycerol Edible Oil on Early Intervention in Diabetic Nephropathy and the Prevention and Treatment of Other Complications

Evaluation of the Effects of Diacylglycerol Edible Oil on Early Intervention in Diabetic Nephropathy and the Prevention and Treatment of Other Complications

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129707
Enrollment
Unknown
Registered
2026-08-07
Start date
2025-07-04
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Interventions

Diacylglycerol Oil Intervention Group:Replace the oil from the stir-fry with the product provided - 80% diglyceride cooking oil

Sponsors

Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with type 2 diabetes according to the 1999 WHO criteria; 2.Diagnosed as stage three diabetic nephropathy using the Mogensen classification; 3.Patients who have been ruled out for kidney damage caused by other reasons; 4.Patients have stably taken medication for at least one month prior to the intervention period and will not adjust medication during the three-month intervention period, with SGOT2 already used for three months; 5. Patients have been using ACEI/ARB for at least one month.

Exclusion criteria

Exclusion criteria: 1.No long-term use of lipid metabolism-affecting drugs in the past 6 months; 2.Abuse of narcotics, psychoactive drugs, or cigarettes in the past 6 months; 3.Complications with diabetic gangrene, ketoacidosis, hyperosmolar coma, thyroid and adrenal diseases, or stress conditions such as trauma, surgery, and infections; 4.Presence of serious, life-threatening primary diseases of the cardiovascular, liver, kidney, or hematopoietic systems, or mental disorders; kidney damage caused by urinary stones, acute or chronic nephritis, pyelonephritis, or urinary tract infections, and primary hypertension; 5.Currently using systemic corticosteroids or nonfinasteride drugs affecting glucose metabolism; 6.Participation in other clinical trials in the past three months or currently participating; 7.Patients deemed unsuitable for the clinical trial for other reasons by the researchers.

Design outcomes

Secondary

MeasureTime frame
Blood Pressure;Blood Lipids;Glycated Hemoglobin (HbA1c);Fasting Plasma Glucose (FPG);Fasting Insulin;

Primary

MeasureTime frame
Urine Microalbumin/Creatinine Ratio;Urinalysis;Serum Creatinine (Cr);Blood Urea Nitrogen ;Serum Uric Acid;Estimated Glomerular Filtration Rate (eGFR);Urine ß2-Microglobulin;24-Hour Urine Biochemistry;Urinary Microalbumin Excretion Rate (24-hour urine);

Countries

China

Contacts

Public ContactYuanyuan Yan

Shanghai Jiao Tong University School of Medicine

yanyuanyuan0801@outlook.com+86 183 2197 0015

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026